2,206 Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by ProShare Advisors LLC

ProShare Advisors LLC decreased its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.9% during the 3rd quarter, Holdings Channel.com reports. The fund owned 117,034 shares of the biopharmaceutical company’s stock after selling 2,206 shares during the quarter. ProShare Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $88,743,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Orbimed Advisors LLC bought a new stake in Regeneron Pharmaceuticals during the first quarter worth $11,358,000. BlackRock Inc. purchased a new stake in Regeneron Pharmaceuticals in the 2nd quarter valued at $5,682,636,000. Contravisory Investment Management Inc. purchased a new stake in Regeneron Pharmaceuticals in the 2nd quarter valued at $6,327,000. Oxbow Advisors LLC bought a new position in Regeneron Pharmaceuticals during the 2nd quarter valued at $3,342,000. Finally, Deutsche Bank AG bought a new position in Regeneron Pharmaceuticals during the 2nd quarter valued at $323,249,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ:REGN opened at $927.89 on Monday. Regeneron Pharmaceuticals, Inc. has a twelve month low of $591.52 and a twelve month high of $935.35. The firm has a market capitalization of $95.54 billion, a PE ratio of 20.49, a P/E/G ratio of 1.57 and a beta of 0.10. The company has a quick ratio of 3.66, a current ratio of 4.06 and a debt-to-equity ratio of 0.08. The company has a 50-day moving average price of $793.30 and a two-hundred day moving average price of $738.05.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 EPS for the quarter, topping the consensus estimate of $16.51 by $3.56. The business had revenue of $5.12 billion during the quarter, compared to the consensus estimate of $4.58 billion. Regeneron Pharmaceuticals had a return on equity of 16.01% and a net margin of 28.51%. The firm’s revenue was up 36.3% compared to the same quarter last year. During the same quarter last year, the company earned $11.83 EPS. Equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 49.10 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 3rd. Shareholders of record on Friday, November 20th will be paid a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date is Friday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio is currently 9.29%.

Insiders Place Their Bets

In related news, Director Huda Y. Zoghbi sold 800 shares of the firm’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $800.00, for a total transaction of $640,000.00. Following the transaction, the director directly owned 1,703 shares of the company’s stock, valued at approximately $1,362,400. This trade represents a 31.96% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marion Mccourt sold 1,215 shares of the company’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total value of $1,032,750.00. Following the completion of the sale, the executive vice president directly owned 13,134 shares of the company’s stock, valued at approximately $11,163,900. This represents a 8.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 8,093 shares of company stock valued at $6,506,845 over the last 90 days. 6.97% of the stock is owned by insiders.

More Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Q3 earnings and revenue beat expectations: Regeneron reported $5.12 billion in revenue, up 36.3% year over year and well above the approximately $4.56 billion analyst consensus. Non-GAAP EPS was $20.07, compared with estimates near $16.42 and $11.83 a year earlier. REGN Q3 Earnings Beat on Dupixent Profits & Eylea HD Growth, Stock Up
• Positive Sentiment: Strong commercial performance: Sanofi-partnered Dupixent generated robust demand, while U.S. Eylea HD sales increased 62% to $699 million and global Libtayo sales rose 51% to $550 million. The results suggest Regeneron’s product portfolio is offsetting competitive and pricing pressures in older treatments. Regeneron Reports Third Quarter 2026 Financial and Operating Results
• Positive Sentiment: Pipeline and strategic momentum: Regeneron highlighted progress toward upcoming FDA catalysts, expanded its Sanofi collaboration with next-generation long-acting immunology antibodies and received a $1 billion upfront payment to be recognized as collaboration revenue. A new Phase 2 cemiplimab combination study also expands its skin-cancer pipeline. Regeneron Expands Skin Cancer Pipeline With New Cemiplimab Combo Trial
• Neutral Sentiment: Management characterized 2026 as potentially one of Regeneron’s strongest years, and analysts have raised some expectations following the earnings beat. Investors will now focus on whether Dupixent growth and new launches can remain durable.
• Negative Sentiment: Eylea 2 mg remains exposed to biosimilar competition, while at least one analyst recently lowered Regeneron’s price target from $900 to $850. After the sharp upward move, valuation and the need for continued execution could create near-term volatility. Evercore ISI Adjusts Price Target on Regeneron Pharmaceuticals

Analyst Ratings Changes

Several analysts have recently commented on the stock. Leerink Partners increased their target price on shares of Regeneron Pharmaceuticals from $641.00 to $824.00 and gave the company a “market perform” rating in a report on Monday, August 17th. The Goldman Sachs Group boosted their price target on shares of Regeneron Pharmaceuticals from $965.00 to $972.00 and gave the stock a “buy” rating in a report on Friday, July 31st. Piper Sandler upped their price objective on shares of Regeneron Pharmaceuticals from $854.00 to $865.00 and gave the stock an “overweight” rating in a research report on Monday, October 19th. UBS Group upgraded Regeneron Pharmaceuticals from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $660.00 to $978.00 in a research note on Thursday, October 15th. Finally, Citigroup lifted their price target on Regeneron Pharmaceuticals from $740.00 to $825.00 and gave the stock a “neutral” rating in a report on Friday. One analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and eight have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $850.83.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.